Smallpox

Agreement signed for vaccinia immune globulin; European alliance announced

Published in Medical Letter on the CDC and FDA, April 13th, 2003

Cangene Corporation (TSX: CNJ) announced that it has concluded an agreement with Acambis plc to market Cangene's vaccinia immune globulin (VIG) product in markets outside of North America and Israel and that it has entered a European marketing and distribution agreement for its WinRho SDF with Baxter Healthcare Corporation

Cangene and Acambis will work together to supply this important product.

Cangene is currently supplying VIG under contract to the U.S. Centers for Disease Control and Prevention (CDC). VIG is used in treating and preventing most severe reactions that may be brought on by the administration of the smallpox vaccine. VIG is an...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-04-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry